Korean J Pathol.  1997 Dec;31(12):1291-1296.

Taxol-induced Pathological Findings in Rat Small Intestine

Affiliations
  • 1Department of Pathology, College of Medicine, Ewha Womans University,Seoul 158-056, Korea.
  • 2Department of Pathology, College of Medicine, Yonsei University, Seoul 120-752, Korea.

Abstract

Taxol is an active chemotherapeutic agent against a variety of solid tumors and a potentially useful drug for augmenting the cytotoxic action of radiotherapy against certain cancers. Taxol blocks cells in the mitotic phase of cell cycle. The aim of this study was to define the in vivo response of rapidly dividing cells of the small intestinal mucosa to taxol. We studied the numbers of apoptotic and mitotic cells and the expression of bcl-2 and p53 in rat jejunal crypt cells at 1, 2, 4, 8, 12, 16, and 24 hours and 3 and 5 days after intraperitoneal injection of taxol. Mitosis peaked at 2 and 4 hours and 12 and 16 hours. Apoptosis peaked at 16 hours and returned to normal after five days. The glands in crypts showed marked distortion with atypical lining cells after three days, which returned to normal at 5 days. bcl-2 expression was markedly decreased at 8 to 24 hours and subnormally recovered after three to five days. p53 showed no significant changes throughout. The histopathological changes in small intestine due to taxol were transient with complete recovery. bcl-2 expression was inversely corresponded to numbers of apoptosis. The changes were p53 independent. Further studies to understand the conditions that maximize the cell-cycle modulating effects of taxol cl-may greatly enhance its anti-tumor effectiveness.

Keyword

Taxol; Small intestine; Mitosis; Apoptosis; bcl-2; p53

MeSH Terms

Animals
Apoptosis
Cell Cycle
Injections, Intraperitoneal
Intestinal Mucosa
Intestine, Small*
Mitosis
Paclitaxel
Radiotherapy
Rats*
Paclitaxel
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr